ClinicalTrials.gg

Program

risankizumab

Also written as “Risankizumab”, “risankizumab IV” and “risankizumab SC”.

Its studies are mostly in Psoriasis · Crohn Disease · Arthritis, Psoriatic · Colitis, Ulcerative · Arthritis, Juvenile, led by 3 companies.

Furthest: phase 4, since May 28, 202168 company-led studies, 16 open or runningNext primary completion: Jan 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie6515 open or runningphase 4since May 28, 2021Apr 10, 2012Jan 2027phase 1 · NCT07466550
Johnson & Johnson21 open or runningphase 3since Mar 23, 2026Oct 11, 2021Nov 15, 2028phase 3 · NCT07499232
Boehringer Ingelheim10 open or runningphase 2since Feb 3, 2014Feb 3, 2014none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Feb 1, 2016.

  1. Oct 20, 2023Phase 3 study in Arthritis, JuvenileAbbVie · NCT06100744 · 40 planned · United States, Australia, Canada and more
  2. Mar 21, 20242 phase 4 studiesAbbVie · NCT06333860, NCT06346288
  3. Jun 28, 2024Phase 1 study in Healthy VolunteersAbbVie · NCT06487572 · 60 enrolled · United States
  4. Aug 8, 2024Phase 2 study in Crohn DiseaseAbbVie · NCT06548542 · 590 planned · United States, Austria, Belgium and more
  5. Aug 23, 2024Phase 1 study in Healthy VolunteersAbbVie · NCT06571266 · 231 enrolled · United States
  6. Mar 4, 2025Phase 2 study in Arthritis, PsoriaticAbbVie · NCT06865105 · 300 planned · United States, Canada, Czechia and more
  7. Mar 12, 2025Phase 3 study in Colitis, UlcerativeAbbVie · NCT06880744 · 573 enrolled · United States, Austria, Bulgaria and more
  8. Apr 4, 20252 phase 1 studiesAbbVie · NCT06937619, NCT06946524
  9. May 28, 2025Phase 1 study in Healthy VolunteersAbbVie · NCT07007091 · 260 enrolled · United States
  10. Jul 8, 2025Phase 3 study in Colitis, UlcerativeAbbVie · NCT07071519 · 120 planned · United States, Belgium, Brazil and more
  11. Mar 9, 2026Phase 1 study in Healthy VolunteerAbbVie · NCT07466550 · 60 planned · United States
  12. Mar 23, 2026Phase 3 study in Crohn DiseasePhase 3 reachedJohnson & Johnson · NCT07499232 · 530 planned · United States, Austria, Belgium and more
  13. Jul 7, 2026Phase 2 study in Crohn DiseaseAbbVie · NCT07697456 · 2,000 planned · United States, Canada, Israel and more
  14. Nov 9, 2026Primary completion moved from 2027-12 to 2029-08Date moved laterphase 2 · +20 months · NCT06865105

Ahead

  1. Jan 2027Primary completion: phase 1 study in Healthy VolunteerAbbVie · NCT07466550
  2. Mar 2027Primary completion: phase 3 study in Crohn DiseaseAbbVie · NCT06063967
  3. Aug 2027Primary completion: phase 3 study in Colitis, UlcerativeAbbVie · NCT06880744
  4. Feb 2028Primary completion: phase 3 study in Crohn DiseaseAbbVie · NCT04524611

TargetBeta

IL12B →IL23A →read by rule
“Interleukin-23 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
guselkumabruleJohnson & Johnsonphase 460
mirikizumabruleEli Lillyphase 436

Studies

The newest 60 of 68 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07697456Crohn Disease · United States, Canada, Israel and more2RecruitingAbbVieOct 20312,000
NCT07499232Crohn Disease · United States, Austria, Belgium and more3RecruitingJohnson & JohnsonNov 15, 2028530
NCT07466550Healthy Volunteer · United States1RecruitingAbbVieJan 202760
NCT07071519Colitis, Ulcerative · United States, Belgium, Brazil and more3RecruitingAbbVieJul 2034120
NCT07007091Healthy Volunteers · United States1CompletedAbbVieJan 15, 2026260
NCT06946524Healthy Volunteers · United States1CompletedAbbVieNov 25, 202559
NCT06937619Healthy Volunteer · United States1CompletedAbbVieNov 10, 2025263
NCT06880744Colitis, Ulcerative · United States, Austria, Bulgaria and more3Active, not recruitingAbbVieAug 2027573
NCT06865105Arthritis, Psoriatic · United States, Canada, Czechia and more2RecruitingAbbVieAug 2029300
NCT06571266Healthy Volunteers · United States1CompletedAbbVieApr 16, 2025231
NCT06548542Crohn Disease · United States, Austria, Belgium and more2RecruitingAbbVieJan 2030590
NCT06487572Healthy Volunteers · United States1CompletedAbbVieFeb 7, 202560
NCT06346288Inflammatory Bowel Diseases · United States, Israel4CompletedAbbVieFeb 5, 202610
NCT06333860Moderate Plaque Psoriasis · United States, Australia, Belgium and more4CompletedAbbVieMar 19, 2026393
NCT06100744Arthritis, Juvenile · United States, Australia, Canada and more3RecruitingAbbVieSep 202640
NCT06063967Crohn Disease · United States, Argentina, Brazil and more3Active, not recruitingAbbVieMar 2027289
NCT06054425Healthy Volunteers · United States1CompletedAbbVieMay 6, 202448
NCT05995353Crohn Disease · United States, Belgium, Bulgaria and more3RecruitingAbbVieApr 2029110
NCT05969223Psoriasis · United States4CompletedAbbVieJan 22, 2025214
NCT05567029Healthy Volunteers · United States1CompletedAbbVieApr 20, 2023198
NCT05305222Healthy Volunteers · United States1CompletedAbbVieJun 15, 201817
NCT05283694Healthy Volunteers · United States1CompletedAbbVieJun 12, 201848
NCT05283681Healthy Volunteers · United States1CompletedAbbVieNov 11, 2019226
NCT05274100Healthy Volunteers · United States1CompletedAbbVieJul 6, 2021394
NCT05274087Healthy Volunteers · United States1CompletedAbbVieApr 7, 202130
NCT05268068Healthy Volunteers · China1CompletedAbbVieApr 26, 202030
NCT05083078Arthritis, Psoriatic · Austria1TerminatedJohnson & JohnsonJul 1, 202211
NCT04908475Psoriasis · United States, Canada, Germany and more4CompletedAbbVieApr 20, 2023352
NCT04862286Psoriasis · United States, Canada, Germany and more3Active, not recruitingAbbVieApr 2028132
NCT04713592Psoriasis · United States, Canada, Puerto Rico and more3CompletedAbbVieApr 20, 2023174
NCT04524611Crohn Disease · United States, Argentina, Australia and more3Active, not recruitingAbbVieFeb 2028527
NCT04451720Psoriasis · Japan3CompletedAbbVieNov 21, 2022119
NCT04435600Psoriasis · United States, Canada, Germany and more3CompletedAbbVieFeb 12, 2024139
NCT04254783Colitis, Ulcerative · United States, Germany, Israel1CompletedAbbVieOct 14, 202220
NCT04102007Plaque Psoriasis · United States, Australia, Germany and more3CompletedAbbVieJan 17, 2022244
NCT03926169Hidradenitis Suppurativa · United States, Australia, Canada and more2CompletedAbbVieFeb 2, 2021243
NCT03875508Psoriasis · United States3CompletedAbbVieApr 24, 2020108
NCT03875482Psoriasis · United States, Puerto Rico3CompletedAbbVieFeb 20, 2020157
NCT03706040Dermatitis · United States, Australia, Canada and more2CompletedAbbVieOct 28, 2020172
NCT03675308Arthritis, Psoriatic · United States, Argentina, Australia and more3Active, not recruitingAbbVieOct 8, 2020964
NCT03671148Arthritis, Psoriatic · United States, Argentina, Australia and more3Active, not recruitingAbbVieJun 22, 2020444
NCT03518047Psoriasis · Russian Federation3CompletedAbbVieFeb 11, 202050
NCT03478787Psoriasis · United States, Canada, France and more3CompletedAbbVieJul 8, 2020327
NCT03398148Colitis, Ulcerative · United States, Argentina, Austria and more3CompletedAbbVieNov 9, 20221,558
NCT03398135Colitis, Ulcerative · United States, Argentina, Austria and more3Active, not recruitingAbbVieSep 20281,242
NCT03255382Psoriasis · Germany3CompletedAbbVieJul 6, 2018120
NCT03219437Psoriasis · Brazil3CompletedAbbVieNov 26, 2021104
NCT03105128Crohn Disease · United States, Argentina, Australia and more3CompletedAbbVieNov 9, 2020931
NCT03105102Crohn Disease · United States, Argentina, Australia and more3Active, not recruitingAbbVieFeb 20291,336
NCT03104413Crohn Disease · United States, Argentina, Australia and more3CompletedAbbVieNov 30, 2020618
NCT03047395Psoriasis · United States, Australia, Austria and more3CompletedAbbVieNov 29, 20232,170
NCT03022045Psoriasis · Japan3CompletedAbbVieSep 17, 201718
NCT03000075Psoriasis2CompletedAbbVieSep 21, 2017182
NCT02986373Arthritis, Psoriatic2CompletedAbbVieJul 8, 2018145
NCT02772601Psoriasis · Germany1CompletedAbbVieJun 15, 201721
NCT02719171Arthritis, Psoriatic2CompletedAbbVieMay 2017185
NCT02694523Psoriasis3CompletedAbbVieAug 2017684
NCT02684370Psoriasis3CompletedAbbVieDec 2016560
NCT02684357Psoriasis3CompletedAbbVieDec 2016577
NCT02672852Psoriasis3CompletedAbbVieAug 2, 2017507

How it is read

Names in the registry

  • “Risankizumab”, 53 entries
  • “risankizumab”, 17 entries
  • “risankizumab IV”, 4 entries
  • “risankizumab SC”, 4 entries
  • “BI 655066”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.